Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis buys another 2.5 percent in Israel’s Gamida Cell

Swiss drugmaker Novartis will invest up to an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said on Sunday.   Novartis last year invested $35 million in the company for a 15 percent stake, in a deal that could reach $600 million if Novartis exercises a buyout option that […]

Read More »

Roche Snaps Up Bay Area’s Adheron in $580 Million Deal

Swiss-based Roche (RHHBY) acquired San Francisco-based Adheron Therapeutics for up to $580 million today.   Adheron focuses on technology that disrupts cell adhesion, which has potential applications for a variety of diseases. Its focus is Cadherin-11 (Cad-11), a surface protein found on fibroblasts in the skin and lungs, and fibroblast-like synoviocytes (FLS) found in the […]

Read More »

AbbVie scraps Galapagos deal to focus on own arthritis drug

AbbVie Inc said its experimental drug improved symptoms of rheumatoid arthritis in mid-stage studies and scrapped plans to buy rights to a similar treatment from Belgium’s Galapagos NV. Galapagos shares were down 27 percent at 40.20 euros in Amsterdam. AbbVie shares rose 2 percent to $57.66 in early trading on Friday. Analysts said the drug’s […]

Read More »

Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

Merck and Pfizer collaborate with Dako in developing an immunohistochemistry (IHC)-based companion diagnostic (CDx) in immuno-oncology     September 24, 2015 05:00 PM Eastern Daylight Time   DARMSTADT, Germany & NEW YORK–(BUSINESS WIRE)–As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the […]

Read More »

Nestle pushes further into medicine with planned Alzheimer’s test

ZURICH (Reuters) – Food group Nestle has taken a further step into the medicine business by signing a research collaboration agreement with a Swiss biotech company to develop an Alzheimer’s disease diagnostic test. Nestle’s second medical deal in a week underscores the commitment by the world’s largest packaged food company to the faster-growing, more profitable […]

Read More »

Craig Venter’s company in deal for whole exome tests at new low cost

A company formed by genome pioneer Craig Venter will offer clients of a South Africa-based insurance company whole exome sequencing –sequencing all protein-making genes in the human genome – at a price that marks yet another dramatic decline in the cost of gene sequencing, the two companies said on Tuesday. Venter’s company, Human Longevity Inc, […]

Read More »

Perrigo recommends shareholders reject Mylan’s tender offer

Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV’s unsolicited $27 billion tender offer, saying it substantially undervalued the company. Mylan first proposed to buy Perrigo in April and, after being repeatedly rebuffed, launched a tender offer on Monday. It has said it would take control if more than […]

Read More »

World’s biggest private biotech Intarcia in no rush to list

Intarcia Therapeutics, with an enviable cash pile to fund development of its matchstick-size implantable drug-delivery pump for diabetes, is happy to sit out the current initial public offering (IPO) boom. The Boston-based group clinched a royalty-based financing deal in April valuing the company at $5.5 billion, more than any other unlisted emerging biotechnology business in […]

Read More »

Nestle enters agreement to develop ulcerative colitis therapy

Nestle is working with Lipid Therapeutics to develop and commercialize a new therapeutic treatment for mild-to-moderate ulcerative colitis, which can causes ulcers, bleeding and pain due to inflammation of the colon, the company said on Wednesday. Nestle Health Science intends to develop an add-on therapy to an existing one that is commonly used but with […]

Read More »

Dental supply maker Dentsply to buy Sirona in $5.56 billion deal

Dentsply International Inc (XRAY.O) said on Tuesday it would merge with peer Sirona Dental Systems Inc (SIRO.O) in a $5.56 billion all-stock deal, creating the world’s largest dental equipment maker. The deal will combine Dentsply’s single-use dental supplies, such as paste and sealants, with Sirona’s advanced technology equipment, such as imaging systems and instruments. “There […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom